Truist Financial Corp Acquires 4,186 Shares of DaVita Inc. $DVA

Truist Financial Corp boosted its stake in shares of DaVita Inc. (NYSE:DVA) by 48.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,832 shares of the company’s stock after buying an additional 4,186 shares during the period. Truist Financial Corp’s holdings in DaVita were worth $1,705,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. NewEdge Advisors LLC lifted its stake in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after purchasing an additional 28,739 shares in the last quarter. Ameritas Advisory Services LLC purchased a new stake in shares of DaVita during the second quarter valued at about $47,000. KLP Kapitalforvaltning AS boosted its holdings in shares of DaVita by 1.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 28,614 shares of the company’s stock valued at $4,076,000 after buying an additional 300 shares in the last quarter. Finally, Aberdeen Group plc grew its position in shares of DaVita by 16.5% in the 2nd quarter. Aberdeen Group plc now owns 49,209 shares of the company’s stock worth $7,010,000 after buying an additional 6,956 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on DVA shares. TD Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday. UBS Group increased their price objective on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday. Barclays boosted their target price on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Truist Financial set a $158.00 price target on DaVita in a research note on Thursday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $160.50.

DaVita Price Performance

NYSE DVA opened at $140.77 on Friday. The company has a market cap of $9.94 billion, a price-to-earnings ratio of 14.20, a PEG ratio of 0.49 and a beta of 0.99. The stock’s fifty day moving average price is $115.12 and its 200 day moving average price is $124.97. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $178.38.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.16. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.During the same quarter in the previous year, the business earned $2.24 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.